Extended Data Fig. 7: Genes involved in inflammation are downregulated upon combined rapamycin and trametinib treatment.

Expression level of inflammation associated genes based on the RNA seq analysis of kidney, spleen and muscle tissue from 24-months-old rapamycin, trametinib and combination treated animals. a–c Cd5l was significantly downregulated in a kidney, b spleen and c muscle upon combination treatment. d, e Ccl8 was significantly downregulated by combination treatment in d kidney and by rapamcin and combination treatment in e spleen and f male muscle. g, h Lyzosyme1 (Lyz1) expression was decreased in g kidney upon trametinib and combination treatment, and h in female spleen upon rapamycin, trametinib and combination treatment. i, j Cxcl7 was significantly downregulated in i male kidney and j male muscle upon combination treatment, and by rapamycin in male muscle. k Cxcl1 expression level was decreased in the female spleen upon rapamycin and combination treatment. l Cxcl13 was significantly downregulated by rapamycin in male muscle tissue. m, n Expression of Cxcl14 was upregulated by rapamycin and the combination treatment in m male and female muscle. n Cxcl14 was significantly downregulated in the female spleen. Data are presented as Mean ± SEM. Statistical analyses were performed using DESeq2/1.24.0. P-values were adjusted for multiple testing. *P < 0.05 and **P < 0.01, ***P < 0.001, and ****P < 0.0001. Number of scored tissues per treatment are indicated in brackets.